AnalystBook Research · Company Intelligence

AVIENT CORP

AVNTNYSE

Built from AVIENT CORP's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Avient held revenue nearly flat and remained cash-generative, but thin profit and inventory growth showed limited operating momentum.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue grew 0.6%OK
  • ProfitabilityNet income declined 51.7% to $81.9M from $169.5MWatch
  • Cash flowFree cash flow grew 44.6% to $195M from $134.9MOK
  • MarginsOperating margin contracted 392 bps to 6.24%Watch
  • AccountingStable specialty materials with thin profitNote
  • Insiders0 purchases and 0 salesNote

Business

Avient develops specialty polymer formulations, colorants, additives, fibers and composites.

Where the revenue comes from

Fiscal 2025, as AVIENT CORP reports it. History and quarterly detail are in the app.

  • Color, Additives and Inks$2.0B
  • Specialty Engineered Materials$1.2B

Leadership changes

From AVIENT CORP's own filings, the day they're filed.

  • Di Salvo · President · appointmenteff. 2026-06-01
  • Ashish Khandpur · Chief Executive Officer · departureeff. 2023-12-01
  • Di Salvo · departure

Latest filings

  • 8-K · Company announcement2026-08-06
  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-05-15
  • 8-K · Company announcement2026-05-07
  • 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about AVIENT CORP, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.